Regional & international: accessibility.
Health Care System
- Visser O.
- Siesling S.
- van Dijk J.
- van Dijck J.A.
Lung Cancer Prevention and Screening
Lung Cancer Diagnosis and Staging
Molecular and Programmed Death-Ligand 1 Testing
Molecular Tumor Board
Criteria voor Centra voor Longkanker patiënten met zeldzame DNA afwijkingen (Criteria for Centers for patients with lung cancer and a rare DNA abnormality).
|Mutation and/or Fusion in NSCLC||Available Drugs (Alphabetical Order)|
|KRAS||Only within clinical trial|
|EGFR||Afatinib, dacomitinib, erlotinib, erlotinib-bevacizumab, erlotinib-ramucirumab, gefitinib, osimertinib|
|ALK||Alectinib, brigatinib, ceritinib, crizotinib, lorlatinib|
|MET exon 14 skipping or amplication||Only within clinical trial/early access program|
|HER2 mutation or amplification||Only within clinical trial|
|RET||Only within clinical trial/early access program|
|NTRK1-3||Only within clinical trial/early access program|
|NRG1||Only within clinical trial|
Criteria immunotherapy section oncology of the NVALT.
Clinical Value of New Drugs: The Palliative, Adjuvant, Specific Toxicity, Quality of Life, Impact of Treatment, Level of Evidence Criteria
|Criteria for adjuvant therapy|
|Primary end point||OS is the most relevant end point|
|Gain in DFS||Evaluation based on DFS is possible; this results in a preliminary advice that needs to be reevaluated after the OS results become available. A positive advice can be retracted if OS results are negative.|
DFS HR should be <0.7
|Gain in OS||Minimum of 3 years of follow-up|
>3% and HR < 0.7
|Criteria for therapy with palliative intent|
|Gain in OS||>12 wk or HR < 0.7|
|Gain in PFS||>12 wk or HR < 0.7|
|ESMO-MCBS grading||Added when available|
|Chronic invalidating||Not specified|
|Impact of treatment||Treatment burden should be acceptable|
|Costs of treatment||Given for a median duration of treatment|
Given for 28 days
Cost difference compared with standard of care
SONCOS norm report: multidisciplinary norms for oncological care in the Netherlands 2019.
- Biesma B.
- Wymenga A.N.M.
- Vincent A.
- et al.
- Peters S.
- Stahel R.A.
- Dafni U.
- et al.
Conclusions and Future Directions
- Population counter.
- Regional & international: accessibility.https://www.volksgezondheidenzorg.info/onderwerp/ziekenhuiszorg/regionaal-internationaal/bereikbaarheid#node-reistijd-minuten-naar-dichtstbijzijnde-ziekenhuisDate accessed: August 26, 2020
- Lung cancer incidence.https://www.iknl.nl/kankersoorten/longkanker/registratie/incidentieDate accessed: September 16, 2020
- Incidence of cancer in the Netherlands 1999/2000: eleventh report of the Netherlands Cancer Registry.https://research.utwente.nl/en/publications/incidence-of-cancer-in-the-netherlands-19992000-eleventh-report-o(Accessed September 16, 2020)
- Lung cancer survival.Accessed September 16, 2020)
- Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.Int J Cancer. 2015; 136: E359-E386
- National prevention agreement.https://www.rijksoverheid.nl/documenten/convenanten/2018/11/23/nationaal-preventieakkoordDate accessed: August 19, 2020
- Smoking figures.
- Reduced lung-cancer mortality with volume CT screening in a randomized trial.N Engl J Med. 2020; 382: 503-513
- Dutch Institute for Clinical Auditing, Jaarrapportage 2017: registraties.https://dica.nl/media/1583/DICA_Jaarrapportage_2017_-_Registraties.pdfDate accessed: August 26, 2020
- Who treats lung cancer? Results from a global survey.Respir Investig. 2017; 55: 308-313
- Implementation of novel molecular biomarkers for non-small cell lung cancer in the Netherlands: how to deal with increasing complexity.Front Oncol. 2019; 9: 1521
- Non-Small Cell Lung Cancer—General.https://richtlijnendatabase.nl/richtlijn/niet_kleincellig_longcarcinoom/algemeen.htmlDate accessed: September 16, 2020
- Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.BMC Cancer. 2020; 20: 291
- Molecular tumor.
- Relevance and effectiveness of molecular tumor board recommendations for patients with non-small-cell lung cancer with rare or complex mutational profiles.JCO Precis Oncol. 2020; 4: 393-410
- De chirurgische behandeling van longkanker via complete VATS-lobectomie, nieuw in Nederland [Surgical treatment of lung cancer with complete VATS lobectomy, new in the Netherlands].Ned Tijdschr Geneeskd. 2008; 152 ([in Dutch]): 1204-1209
- Dutch lung surgery audit: a national audit comprising lung and thoracic surgery patients.Ann Thorac Surg. 2018; 106: 390-397
- Lessons learned from the Dutch Institute for Clinical Auditing: the Dutch model for quality assurance in lung cancer treatment.J Thorac Dis. 2018; 10: S3472-S3485
- Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach.Radiother Oncol. 2013; 107: 267-273
- Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer.N Engl J Med. 2018; 378: 113-125
- Criteria voor Centra voor Longkanker patiënten met zeldzame DNA afwijkingen (Criteria for Centers for patients with lung cancer and a rare DNA abnormality).https://www.nvalt.nl/vereniging/secties/son/concentratie-en-spreiding-van-oncologische-zorg/_/Concentratie%20en%20spreiding%20van%20zorg/SON%20Criteria%20Centra%20Zeldzame%20Mutaties%20longkanker%20finaal%20met%20datum%2021-09-2017.pdfDate accessed: August 26, 2020
- Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.Lung Cancer. 2019; 140: 107-112
- Criteria immunotherapy section oncology of the NVALT.https://www.nvalt.nl/vereniging/secties/son/concentratie-en-spreiding-van-oncologische-zorg/_/Concentratie%20en%20spreiding%20van%20zorg/Criteria%20immunotherapie%20september%202019.pdfDate accessed: August 26, 2020
- NVMO: about the advice.
- ESMO-Magnitude of Clinical Benefit Scale version 1.1.Ann Oncol. 2017; 28: 2340-2366
- Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries.JAMA. 2016; 315: 272-283
- End-of-life communication: a retrospective survey of representative general practitioner networks in four countries.J Pain Symptom Manage. 2014; 47: 604-619:e3
- End-of-life decisions: a cross-national study of treatment preference discussions and surrogate decision-maker appointments.PLoS One. 2013; 8e57965
- End-of-life care in general practice: a cross-sectional, retrospective survey of ‘cancer’, ‘organ failure’ and ‘old-age/dementia’ patients.Palliat Med. 2014; 28: 965-975
- The intensity of hospital care utilization by Dutch patients with lung or colorectal cancer in their final months of life.Cancer Control. 2019; 26 (1073274819846574)
- Is in-hospital mortality higher in patients with metastatic lung cancer who received treatment in the last month of life? A retrospective cohort study.J Pain Symptom Manage. 2019; 58: 805-811
- Relatives of deceased patients with metastatic lung cancer’s views on the achievement of treatment goals and the choice to start treatment: a structured telephone interview study.BMC Palliat Care. 2020; 19: 86
- Chemotherapy and tyrosine kinase inhibitors in the last month of life in patients with metastatic lung cancer: a patient file study in the Netherlands.Eur J Cancer Care (Engl). 2020; 29e13210
- SONCOS norm report: multidisciplinary norms for oncological care in the Netherlands 2019.https://www.nvmo.org/wp-content/uploads/2019/02/SONCOS-normeringsrapport-2019.pdfDate accessed: September 16, 2020
- Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.Lung Cancer. 2019; 134: 34-41
- Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.Ann Oncol Off J Eur Society for Medical Oncology / ESMO. 2011; 22: 1520-1527
- Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.Lancet. 2007; 369: 1929-1937
- Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.J Clin Oncol. 2011; 29: 4320-4326
- Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.Lancet Oncol. 2013; 14: 543-551
- Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II study.Anticancer Res. 2010; 30: 4237-4243
- Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.J Clin Oncol. 2009; 27: 2038-2045
- Randomised phase 3 study of adjuvant chemotherapy with or without Nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.Br J Cancer. 2019; 121: 372-377
- Efficacy of ibandronate loading dose on rapid pain relief in patients with non-small cell lung cancer and cancer induced bone pain: the NVALT-9 trial.Front Oncol. 2020; 10: 890
- A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.Ann Oncol. 2013; 24: 2860-2865
- Prophylactic cranial irradiation versus observation in radically treated stage III non-small-cell lung cancer: a randomized phase III NVALT-11/DLCRG-02 study.J Clin Oncol. 2018; 36: 2366-2377
- A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.Ann Oncol. 2015; 26: 2286-2293
- Randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer failing first-line platinum-based doublet chemotherapy stratified by VeriStrat good versus VeriStrat poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung trial.J Thorac Oncol. 2017; 12: 752-762
- A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14).Lung Cancer. 2017; 108: 9-14
- Lung Cancer Europe: 2020 position paper. Disparities and challenges in access to lung cancer diagnostics and treatment across Europe.https://www.lungcancereurope.eu/2020/02/04/lung-cancer-europe-2020-position-paper-disparities-and-challenges-in-access-to-lung-cancer-diagnosis-and-treatment-across-europe/Date accessed: September 1, 2020
Disclosure: Dr. Hendriks reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Hendriks reports receiving research funding from Roche Genentech, Boehringer Ingelheim, and AstraZeneca (all paid to the institution); has a role on the advisory board of Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Roche Genentech, Pfizer, Takeda, Merck Sharp & Dohme, Boehringer Ingelheim, and Amgen (all paid to the institution); has a role as a speaker in Merck Sharp & Dohme; reports receiving travel/conference reimbursement from Roche Genentech (self); has a role in mentorship program with key opinion leaders funded by AstraZeneca; reports receiving fees for educational webinars from Quadia (self), interview sessions funded by Roche Genentech (paid to the institution), and as local PI of clinical trials of AstraZeneca, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme/Merck, GlaxoSmithKline, Takeda, Blueprint Medicines, Roche Genentech, and Janssen Pharmaceuticals. Dr. Dingemans reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Dingemans has a role on the advisory boards and/or lectures for Roche Genentech, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Pfizer, Bristol-Myers Squibb, Amgen, Novartis, Merck Sharp & Dohme, Takeda, and Pharma Mar (all paid to the institution); and reports receiving research support from Bristol-Myers Squibb, AbbVie, and Amgen (all paid to the institution). Dr. De Ruysscher reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. De Ruysscher reports receiving research funding from Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, and Olink (all paid to the institution); and has a role on the advisory board of Bristol-Myers Squibb, AstraZeneca, Boehringer Ingelheim, Philips, Cellgene, Seattle Genetics, Roche Genentech, Merck, and Pfizer (all paid to the institution). Dr. Aarts reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Aarts reports receiving research grant from Amgen. Dr. Cornelissen reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Cornelissen reports receiving speaker fees from Roche, Bristol-Myers Squibb, and Pfizer and has a role on the advisory board of Roche and Merck Sharp & Dohme. Dr. Schuuring reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. Schuuring reports receiving advisory board and travel expenses from Biocartis, Bristol-Myers Squibb, AstraZeneca, Pfizer, Bayer, Illumina, Janssen Cilag, Agena Biosciences, Novartis, and MSK/Merck (all paid to the institution); reports receiving research grants from CC Diagnostics and Boehringer Ingelheim; and reports receiving travel expenses from Roche Genentech. Dr. van der Wekken reports no conflict of interest related to the current manuscript. Outside of the current manuscript, Dr. van der Wekken reports receiving research grants and personal fees from AstraZeneca, Boehringer Ingelheim, Pfizer, and Takeda (all paid to the institution). The remaining authors declare no conflict of interest.
User LicenseElsevier user license |
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy